Roche turns to Dualitas to find new bispecific approaches for immunology

Dualitas Therapeutics CBO Forbes Huang (L) and CEO Karim Dabbagh September 17, 2026 06:00 AM EDT StartupsDealsPharma Roche turns to Du­al­i­tas to find new bis­pe­cif­ic ap­proach­es for im­munol­o­gy Kyle LaHucik Biotech Correspondent Roche is turn­ing up the heat on its hunt for next-gen­er­a­tion bis­pe­cif­ic an­ti­bod­ies in a deal that will in­volve screen­ing 300,000 new com­bi­na­tions for in­flam­ma­to­ry … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER